These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

678 related items for PubMed ID: 27252271

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T.
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M.
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [Abstract] [Full Text] [Related]

  • 7. Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.
    Tokunaga K, Hagino N.
    Intern Med; 2017 Jul; 56(11):1399-1403. PubMed ID: 28566605
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
    Kishaba T, McGill R, Nei Y, Ibuki S, Momose M, Nishiyama K, Nagano H, Yamashiro S.
    J Med Invest; 2018 Jul; 65(3.4):251-257. PubMed ID: 30282869
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease.
    Gono T, Tanino Y, Nishikawa A, Kawamata T, Hirai K, Okazaki Y, Shibata Y, Kuwana M.
    Int J Rheum Dis; 2019 Aug; 22(8):1582-1586. PubMed ID: 31050194
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
    Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, Sumikawa H, Johkoh T, Nakashima R, Imura Y, Mimori T, Suda T.
    PLoS One; 2015 Aug; 10(3):e0120313. PubMed ID: 25789468
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dermatomyositis Which Was Double Positive for Anti-MDA5 and Anti-ARS Antibodies That Was Successfully Treated by Intensive Immunosuppressive Therapy.
    Hama S, Higashida-Konishi M, Akiyama M, Shimada T, Takei H, Izumi K, Oshima H, Okano Y.
    Intern Med; 2022 Aug; 61(7):1085-1091. PubMed ID: 35370250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.